Of the 29 deceased BRCA2 mutation carriers in the surveillance group, 24% died of BC, 59% of another malignancy—including two deaths due to ovarian cancer and seven due to pancreatic cancer—and 17% died of nonmalignancy-related causes. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.